Stockscreener 앱 받기
1.32
1.49%
-0.02
시간 외 거래:
1.35
0.03
+2.27%
전일 마감가:
$1.34
열려 있는:
$1.34
하루 거래량:
117.80K
Relative Volume:
0.38
시가총액:
$22.01M
수익:
$4.70M
순이익/손실:
$-14.30M
주가수익비율:
-1.074
EPS:
-1.229
순현금흐름:
$-14.82M
1주 성능:
-2.22%
1개월 성능:
-12.00%
6개월 성능:
+38.95%
1년 성능:
+1.54%
1일 변동 폭
$1.25
$1.355
1주일 범위
$1.25
$1.45
52주 변동 폭
$0.8099
$4.07
마커 테라퓨틱스 Stock (MRKR) Company Profile
명칭
Marker Therapeutics Inc
전화
(713) 400-6400
주소
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.32 | 22.34M | 4.70M | -14.30M | -14.82M | -1.229 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
마커 테라퓨틱스 Stock (MRKR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | Canaccord Genuity | Buy |
| 2021-03-25 | 개시 | Piper Sandler | Overweight |
| 2021-03-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-03-01 | 개시 | Janney | Buy |
| 2018-12-03 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
마커 테라퓨틱스 주식(MRKR)의 최신 뉴스
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones - TipRanks
Marker Therapeutics, Inc. 2025 10-K: Clinical-Stage Immuno-Oncology Pipeline, Regulatory Strategy, and Competitive Landscape Overview - Minichart
MARKER THERAPEUTICS, INC. (MRKR) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Marker Therapeutics (MRKR) outlines MAR-T cancer pipeline, MT-601 trials and grant funding - Stock Titan
Marker Therapeutics 10-K: Revenue $3.55M; Net loss $12.18M - TradingView
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income - TradingView
Marker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-Oncology - Quiver Quantitative
MRKR: Net loss widened to $12.2M in 2025 as clinical programs advanced, with cash runway through Q4 2026 - TradingView
Marker Therapeutics (NASDAQ: MRKR) reports 2025 loss and cash runway into late 2026 - Stock Titan
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results - GlobeNewswire
66% lymphoma response rate gives Marker a new data catalyst for 2026 - Stock Titan
Pullback Watch: Can Marker Therapeutics Inc outperform in the next rally2026 Support & Resistance & High Accuracy Investment Signals - baoquankhu1.vn
Aug Weekly: What is the long term forecast for Marker Therapeutics Inc stockPrice Action & AI Driven Stock Reports - baoquankhu1.vn
H.C. Wainwright Sticks to Its Buy Rating for Marker Therapeutics (MRKR) - The Globe and Mail
Marker Therapeutics (NASDAQ: MRKR) seeks approval to raise authorized shares to 130M - Stock Titan
MRKR SEC FilingsMarker Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Will Marker Therapeutics Inc. stock outperform value stocks2025 Big Picture & Weekly Momentum Stock Picks - Naître et grandir
Market Pulse: Does Marker Therapeutics Inc have pricing powerJuly 2025 Reactions & Smart Allocation Stock Tips - baoquankhu1.vn
What is the long term forecast for Marker Therapeutics Inc stockPortfolio Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
MRKR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
MRKR: First-in-class MAR-T cell therapy shows high efficacy and safety in refractory lymphoma - TradingView
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
How buybacks impact Marker Therapeutics Inc. stock value2025 Top Decliners & AI Based Buy/Sell Signal Reports - mfd.ru
Is Marker Therapeutics Inc. stock a safe buy before earningsMarket Weekly Review & Fast Moving Stock Trade Plans - mfd.ru
Marker Therapeutics sets date for 2026 annual shareholder meeting and proposal deadline - Investing.com Nigeria
Marker Therapeutics Sets Date for 2026 Annual Meeting - TipRanks
Portfolio Update: Why is Mattel Inc stock going upJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Hematopoietic Stem Cell Transplantation (HSCT) Market Booming with Rapid Growth Through 2033 | CellGenix GmbH - EIN News
Can BioSig Technologies Inc benefit from deglobalizationPortfolio Performance Report & Safe Entry Trade Reports - baoquankhu1.vn
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology - manilatimes.net
Good Morning America puts Baylor T-cell cancer trial in national spotlight - Stock Titan
Good Morning America Features Baylor College of Medicine - GlobeNewswire
Institution Moves: Should I trade or invest in One Liberty Properties IncJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
MRKR stock up nearly 114% in 3 months: Here's what you need to know - MSN
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Risk Analysis: Can Marker Therapeutics Inc outperform in the next rallyJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn
Published on: 2026-01-20 15:10:37 - baoquankhu1.vn
Whale Trades: Does REBN have consistent dividend growthTrade Risk Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Marker Therapeutics (NASDAQ:MRKR) Cut to “Hold” at Zacks Research - Defense World
Jobs Data: Can PGHL disrupt its industryLayoff News & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Bearish Setup: Is Marker Therapeutics Inc a strong candidate for buy and holdJuly 2025 Final Week & AI Enhanced Trading Signals - baoquankhu1.vn
Is Marker Therapeutics Inc. on track to beat earningsPortfolio Update Report & Weekly Watchlist of Top Performers - bollywoodhelpline.com
High Growth Tech Stocks To Watch In The US Market January 2026 - simplywall.st
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation - simplywall.st
Insider Trends: Will Marker Therapeutics Inc. stock benefit from commodity pricesWeekly Investment Recap & Low Risk Profit Maximizing Plans - Улправда
How sustainable is Marker Therapeutics Inc. stock dividend payout2025 Year in Review & Safe Capital Growth Plans - Улправда
Short Interest Drops in Twinstar Industries Limited After RallyJuly 2025 Opening Moves & Low Volatility Stock Suggestions - Улправда
Will Marker Therapeutics Inc. stock benefit from green energy trendsSell Signal & Real-Time Chart Pattern Alerts - Улправда
How strong is Marker Therapeutics Inc. stock balance sheetWeekly Risk Report & Stepwise Entry and Exit Trade Signals - Улправда
마커 테라퓨틱스 (MRKR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):